Michelle Dawson posts

Post published on Twitter/X on 5 Sep 2021 13:12

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms
Open original post

Information about the link integrated into the post

Clinical trial

Johns Hopkins University, Charlotte's Web, Inc (2023). Cannabidiol (CBD) in Adults With ASD. ClinicalTrials.gov. Johns Hopkins University.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Johns Hopkins University, Charlotte's Web, Inc (2023). Cannabidiol (CBD) in Adults With ASD. ClinicalTrials.gov. Johns Hopkins University.

Publication date
20 Apr 2023
Identifier
NCT05015439
Authors
Johns Hopkins University, Charlotte's Web, Inc
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Johns Hopkins University
Metadata source
clinicaltrials.gov

Abstract

There are no FDA approved treatments for use in adults with autism spectrum disorder (ASD), many of whom have distressing anxiety, mood disturbances, sleep problems, and agitation. Some researchers and individuals with ASD have noted that cannabidiol (CBD) is beneficial for those psychiatric problems. This study is to learn more about the effectiveness and safety of CBD in the treatment of psychiatric problems in adults with ASD. The study will last 14 weeks total, during which six weeks participants will receive a pill containing CBD, two weeks where participants will receive no drug/placebo, and six weeks where participants will receive the placebo, an inactive pill. As part of the study, participants will have regular visits and be asked questions about anxiety, challenging behaviors, daily functioning, cognition, and physical symptoms, on standard assessments.

Open source Link to cited source